Jacek Mackiewicz

1.5k total citations
55 papers, 563 citations indexed

About

Jacek Mackiewicz is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Jacek Mackiewicz has authored 55 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 31 papers in Molecular Biology and 12 papers in Immunology. Recurrent topics in Jacek Mackiewicz's work include Cancer Immunotherapy and Biomarkers (27 papers), CAR-T cell therapy research (23 papers) and Melanoma and MAPK Pathways (22 papers). Jacek Mackiewicz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), CAR-T cell therapy research (23 papers) and Melanoma and MAPK Pathways (22 papers). Jacek Mackiewicz collaborates with scholars based in Poland, United States and Spain. Jacek Mackiewicz's co-authors include Andrzej Maćkiewicz, Tomasz Kolenda, Piotr Rutkowski, Katarzyna Lamperska, Kacper Guglas, Anna Teresiak, Renata Bliźniak, Łukasz Galus, Bożena Cybulska-Stopa and Rafał Suwiński and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Jacek Mackiewicz

52 papers receiving 556 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacek Mackiewicz Poland	13	339	297	148	129	50	55	563
Yixin Liu China	9	173 0.5×	158 0.5×	70 0.5×	104 0.8×	37 0.7×	25	362
Ruozheng Wang China	12	157 0.5×	141 0.5×	97 0.7×	111 0.9×	27 0.5×	47	412
R. Del Moral Spain	10	143 0.4×	211 0.7×	161 1.1×	26 0.2×	37 0.7×	18	433
Mehlika Hazar-Rethinam Australia	11	173 0.5×	321 1.1×	102 0.7×	31 0.2×	16 0.3×	16	428
М. К. Ибрагимова Russia	13	217 0.6×	211 0.7×	118 0.8×	69 0.5×	105 2.1×	78	507
Jay Patrick Lopez United States	10	323 1.0×	299 1.0×	126 0.9×	23 0.2×	43 0.9×	20	555
Youcheng Zhang China	6	338 1.0×	296 1.0×	221 1.5×	45 0.3×	44 0.9×	14	578
Natalie D. Depcik‐Smith United States	4	271 0.8×	448 1.5×	45 0.3×	31 0.2×	63 1.3×	7	670
Katie A. Ashton Australia	12	170 0.5×	224 0.8×	120 0.8×	73 0.6×	29 0.6×	23	457
Mingzi Tan China	16	125 0.4×	339 1.1×	176 1.2×	160 1.2×	65 1.3×	28	615

Countries citing papers authored by Jacek Mackiewicz

Since Specialization

Citations

This map shows the geographic impact of Jacek Mackiewicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacek Mackiewicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacek Mackiewicz more than expected).

Fields of papers citing papers by Jacek Mackiewicz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacek Mackiewicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacek Mackiewicz. The network helps show where Jacek Mackiewicz may publish in the future.

Co-authorship network of co-authors of Jacek Mackiewicz

This figure shows the co-authorship network connecting the top 25 collaborators of Jacek Mackiewicz. A scholar is included among the top collaborators of Jacek Mackiewicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacek Mackiewicz. Jacek Mackiewicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Czarnecka, Anna M., Paweł Teterycz, Magdalena Zielińska, et al.. (2025). Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD. Targeted Oncology. 20(4). 693–705.

Sauer, Natalia, et al.. (2024). Impact of Bisphosphonate Therapy on Oral Health in Patients with Breast and Prostate Cancer and Bone Metastases: A Comprehensive Study. Cancers. 16(6). 1124–1124.

Kisielewska, Katarzyna, et al.. (2024). First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy. SHILAP Revista de lepidopterología. 2. 100153–100153. 1 indexed citations

Luke, Jason J., Paolo A. Ascierto, Muhammad A. Khattak, et al.. (2024). Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of Clinical Oncology. 42(14). 1619–1624. 43 indexed citations

Schadendorf, Dirk, Jason J. Luke, Paolo A. Ascierto, et al.. (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for ImmunoTherapy of Cancer. 12(3). e007501–e007501. 5 indexed citations

Galus, Łukasz, Tomasz Kolenda, Michał Michalak, & Jacek Mackiewicz. (2024). Diagnostic and prognostic role of long non-coding RNAs (lncRNAs) in metastatic melanoma patients with BRAF gene mutation receiving BRAF and MEK inhibitors. Heliyon. 10(7). e29071–e29071. 2 indexed citations

Luke, Jason J., Paolo A. Ascierto, Muhammad Adnan Khattak, et al.. (2023). Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.. Journal of Clinical Oncology. 41(17_suppl). LBA9505–LBA9505. 7 indexed citations

Cybulska-Stopa, Bożena, Anna M. Czarnecka, Marcin Ziętek, et al.. (2023). 1115P Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice. Annals of Oncology. 34. S672–S672. 2 indexed citations

Cybulska-Stopa, Bożena, Marcin Ziętek, Łukasz Galus, et al.. (2023). Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma. Targeted Oncology. 18(2). 235–245. 2 indexed citations

10.

Czarnecka, Anna M., Bożena Cybulska-Stopa, Marcin Ziętek, et al.. (2022). Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients. Cancers. 14(9). 2123–2123. 5 indexed citations

11.

Czarnecka, Anna M., Bożena Cybulska-Stopa, Marcin Ziętek, et al.. (2022). Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence. Journal of Clinical Medicine. 11(8). 2239–2239. 4 indexed citations

12.

Cybulska-Stopa, Bożena, Marcin Ziętek, Anna M. Czarnecka, et al.. (2021). Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. Journal of Dermatological Treatment. 33(4). 2168–2174. 8 indexed citations

13.

Luke, Jason J., Piotr Rutkowski, Paola Queirolo, et al.. (2021). LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Annals of Oncology. 32. S1314–S1315. 13 indexed citations

14.

Cybulska-Stopa, Bożena, Renata Pacholczak‐Madej, Grażyna Kamińska‐Winciorek, et al.. (2020). First-Line Treatment of Advanced/Metastatic Melanoma with Anti-PD-1 Antibodies: Multicenter Experience in Poland. Immunotherapy. 13(4). 297–307. 10 indexed citations

15.

Kolenda, Tomasz, Kacper Guglas, Joanna Sobocińska, et al.. (2020). Liquid lncRNA Biopsy for the Evaluation of Locally Advanced and Metastatic Squamous Cell Carcinomas of the Head and Neck. Journal of Personalized Medicine. 10(3). 131–131. 7 indexed citations

16.

Kolenda, Tomasz, Kacper Guglas, Joanna Sobocińska, et al.. (2020). PRINS lncRNA Is a New Biomarker Candidate for HPV Infection and Prognosis of Head and Neck Squamous Cell Carcinomas. Diagnostics. 10(10). 762–762. 25 indexed citations

17.

Gogas, Helen, Brigitte Dréno, James Larkin, et al.. (2020). Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Annals of Oncology. 32(3). 384–394. 71 indexed citations

18.

Cybulska-Stopa, Bożena, Iwona Ługowska, Rafał Wiśniowski, et al.. (2020). Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy. Współczesna Onkologia. 24(1). 34–41. 12 indexed citations

19.

Krokowicz, Łukasz, et al.. (2015). In vitro studies of antibacterial and antifungal wound dressings comprising H2TiO3 and SiO2 nanoparticles. Polish Journal of Microbiology. 64(2). 137–142. 6 indexed citations

20.

Krokowicz, Łukasz, et al.. (2014). Management of traveller’s diarrhoea with a combination of sodium butyrate, organic acids, and A-300 silicon dioxide. Gastroenterology Review. 5(5). 285–290. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact